Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Basilea Pharmaceutica's Debt-to-EBITDA or its related term are showing as below:
XSWX:BSLN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -41.15 Med: -1.47 Max: 103.72
Current: 1.75
During the past 13 years, the highest Debt-to-EBITDA Ratio of Basilea Pharmaceutica was 103.72. The lowest was -41.15. And the median was -1.47.
XSWX:BSLN's Debt-to-EBITDA is ranked worse than 56.01% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs XSWX:BSLN: 1.75
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Basilea Pharmaceutica Debt-to-EBITDA Related Terms
Basilea Pharmaceutica Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Basilea Pharmaceutica (XSWX:BSLN) has a Debt-to-EBITDA of 1.55 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Basilea Pharmaceutica. According to the industry distribution chart, Basilea Pharmaceutica ranks #163 out of 291 companies in the Biotechnology industry, placing it in the top 56%.
Is Basilea Pharmaceutica's Debt-to-EBITDA too high?
Basilea Pharmaceutica's current Debt-to-EBITDA is 1.55. The Biotechnology industry median Debt-to-EBITDA is 1.14. Basilea Pharmaceutica's value of 1.55 is 36% above this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #163 out of 291 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Basilea Pharmaceutica has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #163 out of 291 companies for Debt-to-EBITDA. This places Basilea Pharmaceutica in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. Basilea Pharmaceutica's value of 1.55 is 36% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current Debt-to-EBITDA of 1.55 is 36% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Basilea Pharmaceutica. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Debt-to-EBITDA is 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.97, compared to a current price of CHF52.40 — trading 9.6% below its estimated fair value. The current Debt-to-EBITDA is 1.55 and 36% above the Biotechnology industry median of 1.14. Basilea Pharmaceutica's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Debt-to-EBITDA is 1.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF52.40 is trading 9.6% below its estimated GF Value™ of CHF57.97.
GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.
Key valuation signals for XSWX:BSLN:
Debt-to-EBITDA: 1.55
GF Value™: CHF57.97 vs. price of CHF52.40 (9.6% below fair value)
Industry Position: 36% above the Biotechnology median (#163 of 291)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
60GF Score
Get the complete analysis for XSWX:BSLN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
